IOL Chemicals & Pharmaceuticals Ltd.

IOL Chemicals & Pharmaceuticals Ltd.

171.36
INR
-2.88
(-1.65%)
5.72EPS
25.40P/E
42.65BMarket Cap
Nov 06Next Earn
IOL Chemicals & Pharmaceuticals Ltd.
NSE:IOLCP
(National Stock Exchange of India)

Recent

price

171.36

P/E

ratio

25.40

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
INR
30.28
36.61
36.88
41.4
19.3
22.04
24.97
34.24
58.89
65.52
66.73
73.87
75.01
72.19
70.46
78.62
85.87
Revenue per Share
0.48
0.37
0.12
0.24
-3.34
-1.52
0.17
0.99
8.42
12.7
15.24
5.71
4.74
4.58
3.44
4.69
5.72
Basic EPS, GAAP
-3.66
-2.63
2.62
4.76
-2.65
-0.34
2.17
2.54
7.57
13.73
9.31
-2.05
-3.05
0.53
-1.19
1.41
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.72
0.81
1.2
0.8
1
0.8
1
- -
Dividend per Share
13.4
13.5
13.23
14.52
8.7
6.56
6.71
7.68
16.68
28.6
42.94
47.44
51.37
54.9
57.5
61.27
- -
Book Value per Share
13.4
13.5
13.22
14.51
8.68
6.52
6.68
7.64
16.65
28.58
42.92
47.32
51.06
54.47
57.03
60.77
- -
Tangible Book Value per Share
129
129
131
136
199
263
281
281
281
284
292
294
294
294
294
294
294
Basic Weighted Avg Shares
3,894
4,707
4,815
5,635
3,847
5,804
7,018
9,621
16,550
18,635
19,461
21,684
22,017
21,190
20,682
23,078
25,236
Sales/Revenue/Turnover
-97.68
9.52
11.98
11.38
-4.58
3.76
10.36
9.35
22.8
28.88
28.42
9.97
8.18
7.93
6.31
8.22
9.06
Operating Margin (%)
238
239
314
316
289
297
298
302
323
357
389
433
462
629
720
803
818
Depreciation Expense
62
48
16
33
-667
-400
47
277
2,367
3,613
4,446
1,677
1,391
1,344
1,011
1,376
1,681
Net Income, GAAP
31.67
- -
46.3
35.08
- -
- -
21.25
11.5
29.59
32.25
22.2
25.43
26.24
26
26.74
25.34
25.46
Effective Tax Rate (%)
1.59
1.01
0.33
0.59
-17.32
-6.9
0.67
2.88
14.3
19.39
22.84
7.73
6.32
6.34
4.89
5.96
6.66
Profit Margin (%)
-25
-260
228
44
749
771
870
800
2,274
3,943
7,317
5,674
4,641
5,598
5,414
5,375
- -
Working Capital
2,352
2,699
2,868
2,204
2,771
3,007
2,850
2,581
1,899
27
18
2
- -
- -
- -
24
- -
LT Debt
1,723
1,736
1,730
2,093
2,072
1,844
1,887
2,157
4,743
8,135
12,604
13,925
15,077
16,115
16,877
17,986
- -
Total Equity
-63.02
- -
0.3
0.61
- -
- -
0.68
12.43
37.81
44.44
40.09
11.08
8.77
7.7
5.54
7.11
- -
Return on Invested Capital (%)
7.6
- -
0.3
7.32
- -
- -
8.44
12.56
38.62
45.62
41.69
12.56
9.72
8.82
6.28
7.76
- -
Return on Capital (%)
3.86
2.75
0.92
1.73
-32.01
-20.44
2.5
13.7
68.6
56.11
42.87
12.64
9.6
8.62
6.13
7.9
- -
Return on Common Equity (%)

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
1,330
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
24
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
294
294
294
Market Capitalization
24,146
21,360
42,647

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
12,276
- -
Cash, Cash Equivalents & STI
- -
1,616
- -
Accounts Receivable, Net
- -
6,031
- -
Inventories
- -
3,711
- -
Total Current Liabilities
- -
6,902
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
1,330
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
29.99%
7.39%
6.57%
Free Cash Flow
-124.4%
-146.61%
-218.32%
Net Income, GAAP
114.04%
-14.27%
36.18%
Sales/Revenue/Turnover
16.54%
3.68%
11.59%
Total Cash Common Dividend
- -
9.32%
25%

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
5,024
5,258
5,233
5,278
20,682
2026
5,517
5,675
5,804
6,195
23,078
2027
7,563
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
1.02
0.65
0.7
1.07
3.44
2026
1.16
1.02
0.7
1.81
4.69
2027
2.19
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
0.8
2026
- -
- -
- -
- -
1
2027
- -
- -
- -
- -
- -
Business
IOL Chemicals and Pharmaceuticals Limited is a prominent Indian pharmaceutical and specialty chemicals manufacturer, serving both domestic and international markets. The company operates through distinct chemical and pharmaceutical divisions. Its pharmaceutical segment focuses on producing a wide array of active pharmaceutical ingredients (APIs), including ibuprofen, paracetamol, metformin, fenofibrate, lamotrigine, clopidogrel bisulphate, pantoprazole sodium, ursodeoxycholic acid, losartan potassium, and gabapentin. These APIs are crucial for treatments targeting conditions such as inflammation, pain relief, fever reduction, diabetes management, anti-platelet therapy, cholesterol regulation, seizure control, hypertension, and proton pump inhibition. Notably, the company is recognized as a significant global producer of Ibuprofen, holding a substantial share of the world market. The chemical division offers specialty industrial chemicals like ethyl acetate, iso butyl benzene, acetyl chloride, and mono chloro acetic acid. These compounds find extensive applications across diverse sectors, including food processing, flexible packaging, pharmaceuticals, textiles, ink, paint, pesticides, and the production of chemical intermediates. IOL Chemicals and Pharmaceuticals Limited, established in 1986, is headquartered in Ludhiana, India, and emphasizes backward integration, innovation, and sustainable manufacturing practices in its operations. The company supplies its high-quality APIs to over 80 countries globally. Recent corporate activities include a consideration of a stock split in late 2024 to enhance share affordability.IOL Chemicals and Pharmaceuticals Limited operates as a significant producer and supplier of both pharmaceutical and chemical products across India and internationally. The company functions through specialized segments catering to distinct industrial requirements. Within its pharmaceutical division, a comprehensive range of active pharmaceutical ingredients (APIs) are manufactured, encompassing products such as ibuprofen, its derivatives like ibuprofen lysinate and ibuprofen sodium, as well as metformin hydrochloride, clopidogrel bisulphate, pantoprazole sodium, ursodeoxycholic acid, losartan potassium, gabapentin, levetiracetam, lamotrigine, fenofibrate, and paracetamol. These critical ingredients are utilized in various therapeutic applications, including anti-inflammatory, analgesic, and antipyretic treatments, managing diabetes, anti-platelet aggregation, cholesterol control, anti-convulsant therapy, anti-cholelithic conditions, and as proton pump inhibitors. The company stands out as a major global supplier of Ibuprofen. The specialty industrial chemicals segment provides essential compounds such as ethyl acetate, iso butyl benzene, acetyl chloride, and mono chloro acetic acid, among others. These chemicals are vital components for industries like food processing, flexible packaging, other pharmaceutical manufacturing, textiles, ink production, paint formulation, pesticide manufacturing, and serving as chemical intermediates. Established in 1986, IOL Chemicals and Pharmaceuticals Limited maintains its principal office in Ludhiana, India, and is recognized for its integrated operations, focus on innovation, and commitment to sustainable production methods. The company has a global reach, exporting its high-quality APIs to over 80 nations. In recent strategic developments, the company considered a stock split in late 2024 to improve share accessibility for a broader investor base.